Show simple item record

Promoter Attenuation in Gene Therapy: Interferon-γ and Tumor Necrosis Factor-α Inhibit Transgene Expression

dc.contributor.authorQin, Lihuien_US
dc.contributor.authorDing, Yaozhongen_US
dc.contributor.authorPahud, Dominique R.en_US
dc.contributor.authorChang, Eugeniaen_US
dc.contributor.authorImperiale, Michael J.en_US
dc.contributor.authorBromberg, Jonathan S.en_US
dc.date.accessioned2009-07-10T19:00:00Z
dc.date.available2009-07-10T19:00:00Z
dc.date.issued1997-11-20en_US
dc.identifier.citationQin, Lihui; Ding, Yaozhong; Pahud, Dominique R.; Chang, Eugenia; Imperiale, Michael J.; Bromberg, Jonathan S. (1997). "Promoter Attenuation in Gene Therapy: Interferon-γ and Tumor Necrosis Factor-α Inhibit Transgene Expression." Human Gene Therapy 8(17): 2019-2029 <http://hdl.handle.net/2027.42/63157>en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/63157
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=9414251&dopt=citationen_US
dc.description.abstractOverview summary Transgene expression can be eliminated even in the presence of substantial amounts of vector DNA in the transduced cells, which suggests that mechanisms other than the antigen-specific immune response may mediate non-cytodestructive events that determine the presence of transgene expression. Our data indicate that the cytokines interferon-γ) (IFN-γ) and tumor necrosis factor-α (TNF-α) inhibit transgene expression from certain widely used viral promoters/enhancers (human cytomegalovirus immediate early, Rous sarcoma virus long terminal repeat, simian virus 40, Moloney murine leukemia virus long terminal repeat) delivered by adenoviral, retroviral, or plasmid vectors in vivo. Inhibition is at the mRNA level and cytokines do not cause vector DNA degradation, inhibit total cellular protein synthesis, or kill infected/transfected cells. Thus, cytokine-regulated promoter function rather than specific immune destruction could limit transgene expression. These results have significant implications for the construction of transfer vectors for human gene therapy because gene transfer vectors could be exposed to a cytokine-rich environment when they are administered in vivo.en_US
dc.format.extent2080871 bytes
dc.format.extent2489 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherMary Ann Liebert, Inc., publishersen_US
dc.titlePromoter Attenuation in Gene Therapy: Interferon-γ and Tumor Necrosis Factor-α Inhibit Transgene Expressionen_US
dc.typeArticleen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid9414251en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/63157/1/hum.1997.8.17-2019.pdf
dc.identifier.doidoi:10.1089/hum.1997.8.17-2019en_US
dc.identifier.sourceHuman Gene Therapyen_US
dc.identifier.sourceHuman Gene Therapyen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.